stated, "We are very pleased to
submit the clinical trial application for the EV 71 vaccine to the SFDA. Our
ability to submit the application ahead of the projected 2010 timeline is a
validation of the R&D capabilities of the team developing this vaccine. A
vaccine against EV 71 represents a significant unmet medical need, given that
there are not effective preventive therapeutic alternatives for this life
threatening viral illness affecting infants and children. Based on current
expectations, we anticipate that the EV 71 vaccine, subject to positive human
clinical trial results and commercialization, represents a significant
flagship product opportunity for the Company as well as an opportunity to
improve the lives of children around the world."
About EV 71
Enterovirus 71, or EV 71, causes Hand, Foot, and Mouth Disease (or HFMD).
More than 90% of the reported cases occur in children under five years old.
HFMD is a common and usually mild childhood disease. EV 71 is a frequent cause
of HFMD epidemics associated with neurological disease in a small proportion
of cases. A number of outbreaks of EV 71 HFMD in the Asia-Pacific region have
been reported since 1997. Outbreaks have been reported in Malaysia (1997),
Taiwan (1998, 2000 & 2001), Mainland China (1998-2008), Australia (1999) and
Singapore (2000) among other areas in the region. There is no specific
treatment for enterovirus infections and a vaccine is not currently available.
In 2008, 489,073 cases were reported in China with 126 reported fatalities.
For the first 11 months of 2009, over 1.1 million cases were reported in China,
with over 400 reported fatalities.
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's vaccine
products include Page: 1 2 3 4 Related biology technology :1
. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television2
. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities3
. Sinovac Reports Unaudited Third Quarter 2009 Financial Results4
. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government5
. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong6
. Sinovac to Present at 2009 UBS Global Life Sciences Conference7
. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine8
. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government9
. Sinovac Obtains Production License for H1N1 Vaccine10
. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results11
. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials